Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Using albumin-bound paclitaxel and nedaplatin in the advanced or recurrent metastasis cervical cancer, to evaluate the efficacy and toxic reaction.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Treatments: Albumin-Bound Paclitaxel; Nedaplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Cervical cancer, advanced or recurrent metastasis

• Measurable and assessible tumor lesions

• Used ordinary paclitaxel or platinum drugs, more than 28 days

• Aged 18-70

• KPS score> 60 points, expected to survive more than 3 months

• Normal bone marrow function

• The function of liver and kidney had no obvious damage

• Normal function of vital organs

• No brain metastases

• Patients or their agents to sign informed consent

• Compliance, and can be followed up regularly

Exclusion Criteria:

• Brain metastases

• Serious complications

• Acute inflammatory response

• Combined with other tumor

• Pregnancy or breast-feeding women

• Vertebral metastasis with nerve compression symptoms

• Large volume of pleural effusion, pericardial effusion

• Other malignancy within five years

• Drug allergy

• Other chemotherapy contraindications

• The possibility of pregnancy, and not willing to contraception

• No measurement of lesion

• Mental illness which is difficult to control